Evaluating acridones as novel therapeutics for human babesiosis
antibabesial activity and represent promising lead chemotypes for therapeutic development. To advance these candidates, future studies focused on optimizing their pharmacokinetic properties and evaluating synergistic combination regimens will be essential for progressing toward effective treatments for human babesiosis.
Authors
- Choukri Ben Mamoun (ORCID: https://orcid.org/0000-0001-5028-1400)
- Pratap Vydyam (ORCID: https://orcid.org/0000-0003-4944-6006)
- Jane X. Kelly (ORCID: https://orcid.org/0000-0001-8871-0207)
- Papireddy Kancharla (ORCID: https://orcid.org/0000-0002-6381-1236)
- Rozalia A. Dodean (ORCID: https://orcid.org/0000-0001-5002-4607)
- Elizabeth Zhang
- Anasuya C. Pal
Institutions
- Portland State University (US)
- Yale University (US)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2026-04-27
- DOI
- https://doi.org/10.1128/aac.00016-26
- Primary Topic
- Trypanosoma species research and implications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- U.S. Department of Veterans Affairs
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases